

LIF Activated Jak Signaling Determines Esrrb Expression During Late-Stage Reprogramming

Delun Huang^{1, 2¶}, Ling Wang^{1¶}, Jingyue Duan¹, Chang Huang¹, Xiuchun (Cindy) Tian¹, Ming Zhang^{2*}, Young Tang^{1*}

¹ Department of Animal Science, Institute for Systems Genomics, University of Connecticut, Storrs, CT, USA.; ² Animal Reproduction Institute, Guangxi University, Nanning, Guangxi, P. R. China.

¶: These authors contributed equally to this study

Author Contributions:

D. H., L. W.,: Collection and assembly of data, Data analysis and interpretation, Manuscript writing

J. D., C. H., X. T.: Collection and assembly of data, Data analysis and interpretation

M. Z., Y. T.: Conception and design, Financial support, Collection and assembly of data, Data analysis and interpretation, Manuscript writing, Final approval of manuscript

* Corresponding Authors:

Ming Zhang, Ph.D., Email: mingzhang@gxu.edu.cn; and

Young Tang, Ph.D., Email: yong.tang@uconn.edu

Abstract

The regulatory process of naïve-state induced pluripotent stem cells (iPSCs) generation is not well understood. Leukemia inhibitory factor (LIF) activated Janus kinase/signal transducer and activator of transcription 3 (Jak/Stat3) is the master regulator for naïve-state pluripotency achievement and maintenance. The estrogen-related receptor beta (*Esrrb*) serves as a naïve-state marker gene regulating self-renewal of embryonic stem cells (ESCs). However, the inter-connection between *Esrrb* and LIF signaling for pluripotency establishment in reprogramming is unclear. We screened the marker genes critical for complete reprogramming during mouse iPSC generation and identified genes including *Esrrb* that are responsive to LIF/Jak pathway signaling. Overexpression of *Esrrb* resumes the reprogramming halted by inhibition of Jak activity in partially reprogrammed cells (pre-iPSCs), and leads to the generation of pluripotent iPSCs. We further show that neither *Nanog* overexpression nor stimulation of Wnt signaling, two upstream regulators of *Esrrb* in ESCs, stimulates the expression of *Esrrb* in reprogramming when LIF or Jak activity is blocked. Our study demonstrates that *Esrrb* is a specific reprogramming factor regulated downstream of LIF/Jak signaling pathway. These results shed new light on the regulatory role of LIF pathway on complete pluripotency establishment during the iPSC generation.

Introduction

Generation of induced pluripotent stem cells (iPSCs)(Takahashi and Yamanaka, 2006) leads to the establishment of pluripotency equivalent to embryonic stem cells (ESCs) without embryo destruction, by overexpressing the so-called Yamanaka factors, namely Oct4, Klf4, Sox2, and c-Myc (OKSM). However, to date, a complete understanding to pluripotency establishment has not been achieved. The cytokine leukemia inhibitory factor (LIF) activates Janus kinas/signal transducer and activator of transcription 3 (Jak/Stat3) pathway, which serves as a key for the self-renewal of naïve-state pluripotent mouse ESCs(Matsuda et al., 1999; Nichols and Smith, 2009; Niwa et al., 1998; Smith et al., 1988; Williams et al., 1988). Stat3 activity also plays a fundamental role for naïve-state iPSC generation at late-reprogramming stage(Tang et al., 2012; van Oosten et al., 2012; Yang et al., 2010). A number of genes have been reported to be regulated by Stat3 and mediate LIF-independent mouse ESC self-renewal or iPSC reprogramming. These include MnSOD, Klf4, Klf5, Nanog, Gbx2, Pim1, Pim3, Prame17, Tfcp2l1, c-Myc, and Foxm1(Aksoy et al., 2007; Cartwright et al., 2005; Casanova et al., 2011; Festuccia et al., 2012; Hall et al., 2009; Martello et al., 2013; Niwa et al., 2009; Parisi et al., 2008; Sheshadri et al., 2015; Tai and Ying, 2013; Tan et al., 2014; Ye et al., 2013). We also found that Jak/Stat3 regulates key epigenetic change during the reprogramming process(Tang et al., 2012). However, question remains as how exactly Jak/Stat3 activity regulates pluripotency establishment during the reprogramming process. A better

understanding to the Stat3 regulated downstream targets/effectors is necessary, which will further facilitate the naïve-state iPSC generation across different species including humans(De Los Angeles et al., 2012).

The nuclear receptor estrogen-related receptor beta (Esrrb) is a canonical Wnt pathway effector negatively regulated by glycogen synthase kinase 3 (GSK3)/T-cell factor 3 (Tcf3) in naïve-state ESCs, and its overexpression can sustain ESC self-renewal that mimics the inhibition of GSK3(Martello et al., 2012). In ESCs, the expression of Esrrb can also regulated by Nanog, and overexpressing Esrrb promotes complete reprogramming from Nanog-null partially reprogrammed iPSCs (pre-iPSCs), and can sustain LIF-independent ESC self-renewal similarly as Nanog(Festuccia et al., 2012). Nanog is not a GSK3 downstream effector (Martello et al., 2012; Silva et al., 2009). This indicates that Esrrb is subjected to multi-upstream signaling regulation for pluripotency establishment and maintenance. However, whether Esrrb is regulated under LIF mediated Jak/Stat3 signaling during the reprogramming process is not clear. In this study we screened the expression of key pluripotency genes regulated by Jak/Stat3 and LIF activities in reprogramming. We describe the identification of Esrrb as an important effector downstream of LIF/Jak/Stat3 signaling for completely reprogrammed iPSC generation, with its expression dependent on LIF pathway activation.

Materials and Methods

Chemicals and DNA Constructs

Doxycyclin (Dox) and Jak inhibitor (Jaki) were purchased from Merck Millipore (Billierica, MA). CHIR99021 and PD0325901 were purchased from SelleckChem (Houston, TX). The LIF neutralizing antibody (LIFAb) was from R&D Systems (Minneapolis, MN). The retro- and lenti-viral vectors including pMXs-Nanog, and FUW-M2rtTA, and the viral packaging plasmids PUMVC, psPAX2 and pCMV-VSV-G(Stewart et al., 1992) were all obtained from Addgene (Cambridge, MA). FUW-TetO-Esrrb and pMXs-Stat3C were described before(Tang et al., 2014; Tang et al., 2012). Nr5a2 cDNA was PCR amplified using primers (forward primer: 5'-AGTTAATTAAGGATCCATGTCTTCTAATTCAGATACTGGGG-3' and reverse primer: 5'-ACTGTGCTGGCGGCCGCTTATGCTCTTTTGGCATGCAAC-3') and cloned into linearized pMXs vectors (Cell Biolabs, San Diego, CA) using the In-Fusion kit (Clontech Inc., Mountain View, CA). Lenti- and retro-viruses were prepared with 293T cells according to the protocol from Addgene and filtered with 0.8 μ m filters.

Cell Culture and Pre-iPSC Reprogramming Assay

R1-ESCs were cultured in 2i/LIF medium(Ying et al., 2008) containing N2B27 medium with 1 μ M PD0325901, 3 μ M CHIR99021, 1 x β -mercaptoethanol (Millipore), 1,000 U/mL mouse LIF (Millipore) and 0.5 x penicillin/streptomycin (Invitrogen, Grand Island, NY). The induced iPSCs were initially cultured in knockout serum replacement (KSR)-

ESC medium after picking and switched to 2i/LIF medium from passage 2. The KSR-ESC medium consists of 76% KO-DMEM, 20% KSR, 1% 100 x Glutamax, 1% 100 x non-essential amino acids, 0.5 x penicillin/streptomycin (all from Invitrogen) and supplemented with 1% 100 x β -mercaptoethanol and 1,000 U/mL mouse LIF.

Generation of the Jaki-treated pre-iPSCs was described previously (Tang et al., 2012) where the OG-MEFs were reprogrammed with OKSM in the presence of 1 μ M Jaki. Single pre-iPSCs colonies were picked and expanded in KSR-ESC medium containing mouse LIF and 1 μ M Jaki (thereafter called KSR-ESC-Jaki medium). Reprogramming assay was performed in KSR-ESC-Jaki medium or the KSR-ESC medium containing no LIF but 2.5 μ g/mL mouse LIF neutralizing antibodies (KSR-ESC-LIFAb medium). For the reprogramming assay, on day -1, 0.25 million pre-iPSCs were seeded into one whole 24-well-plate in which mitomycin C treated CD1 MEF feeders were plated beforehand. On day 0 the cells were infected with retro- or lenti-viral vector control or the genes of interest in the presence of polybrene (American BIO, Natick, MA, USA) overnight. Starting from day 1, KSR-ESC-Jaki medium or the KSR-ESC-LIFAb medium was applied for reprogramming. Application of CHIR99021 for WNT activation or Dox for induced expression was started on day 2. Media were replaced every other day. GFP-expressing colonies were counted between 12 days to 3 weeks after initial viral transduction under a Nikon fluorescence microscope. GFP positive iPSC colonies were picked at 3 weeks after viral transduction and expanded for further characterization.

Embryoid Body (EB) Formation

Established iPSCs lines (passage 3) were passaged onto CD1 MEF feeders. Colonies were trypsinized and single cells were plated back to the tissue culture dish for 2 hours to allow MEFs to attach. The iPSC cells in supernatant were then transferred to a low adhesive Petri-dish and allowed to form EBs and differentiate in 10% FBS in DMEM without LIF. Upon 1 week of differentiation, the EBs were re-plated to 0.1% gelatin (Millipore)-coated tissue culture dish for another week before proceeding to RNA extraction and qRT-PCR.

Quantitative Reverse-Transcription PCR (qRT-PCR) Analysis

Total RNAs were extracted using Trizol (Invitrogen). 1 µg total RNAs were reverse transcribed with All-in-One cDNA Synthesis SuperMix (Bimake, Houston, TX). 2 X SYBR Green PCR Master Mix (Bimake) was used for qRT-PCR. Samples were run using an ABI 7500 Fast instrument, and data were analyzed using 7500 software version 2.0.2 provided with the instrument. All genes were normalized with GAPDH as internal control and relative mRNA expressions were quantified using R1-ESCs as the reference as specified in each figure legend.

Immunostaining

The mouse iPSCs differentiated with EB-mediated method in Gelatin-coated dish were fixed with 4% paraformaldehyde plus 1% sucrose in PBS, following which the cells were treated with 0.5% TX-100 to permeabilize the cell membrane and blocked with donkey

serum. Then the cells were incubated with the antibodies (R&D system, Minneapolis, MN) against three germ layer makers including Otx2 for ectoderm, Brachyury for mesoderm and Gata6 for endoderm. The cell nuclei were counterstained with DAPI and fluorescent images were visualized using a Nikon fluorescent microscope.

Data Analysis

The RNA-seq data were from previous study (GEO access number - GSE97261)(Wang et al., 2017b). Data analyzed through Pearson correlation coefficient were created by R Package, which was in turn used to generate the heatmap. qRT-PCR and cell counting data were processed using One-Way ANOVA with Tukey's multiple comparisons, or the Student's T-test. Figures were presented as mean \pm standard deviation (s.d.). A p-value $<$ 0.05 is considered statistically significant.

Results

Esrrb Is Activated by LIF/Jak Signaling during the Reprogramming Process

Previous studies of reprogramming dynamics towards naïve-state pluripotency have identified a number of pluripotent genes which expression in reprogramming stringently marks the development to pluripotent iPSC state(Buganim et al., 2012; Polo et al., 2012). These genes include Esrrb, Utf1, Lin28a, Dppa2, Nr5a2, Eras, Rex1/Zfp42, Dnmt3l, Pecam1, Nanog, and Epcam(Buganim et al., 2012; Polo et al., 2012). To understand the expression of these genes relevant to Jak/Stat3 activity in reprogramming, we utilized the

RNA-seq data recently generated by us (GEO access number - GSE97261)(Wang et al., 2017b), where we blocked the Jak/Stat3 activity using a well studied Jak-specific inhibitor (Jak inhibitor I, Jaki(Niwa et al., 2009; Thompson et al., 2002)) during the reprogramming of mouse embryonic fibroblasts (MEFs) to iPSCs (Fig. 1A). These MEFs have GFP expression controlled by the Oct4 distal enhancer region (OG-MEFs), and total RNAs of reprogrammed OG-MEFs were analyzed on reprogramming day 18 (Stage 1, S1) and 3-week (S2) after retroviral OKSM infection (Fig. 1A). Heatmap analysis of the RNA-seq data reveals that the majority of the eleven pluripotency-predicting genes are downregulated by Jaki inhibition at 3-week of reprogramming (Fig. 1B). qRT-PCR analysis further confirmed that except for three genes (Utf1, Eras, and Epcam), all other pluripotent markers including Esrrb are significantly upregulated at 3-week of reprogramming in DMSO control, but inhibited when Jak/Stat3 activity is blocked (Fig. 1C).

We previously showed that similar to the Jaki treatment, deprivation of LIF cytokine (no LIF and feeder-cell free) during OG-MEF reprogramming resulted in the generation of only GFP-negative colonies(Tang et al., 2012). If the stimulation of these pluripotency-predicting genes in reprogramming is specifically controlled by Jak/Stat3 activity, we shall observe similar results when LIF cytokine, the stimulator of Jak/Stat3 signaling is depleted during the mouse iPSC induction. We then compared the expression of these genes in MEFs reprogrammed by retroviral OKSM transduction and with or without LIF cytokine at 3-week time point (Figs. 1D, 1E). Indeed we found that the expressions of these genes are significantly inhibited by depletion of LIF cytokine, to levels comparable

to the Jaki treatment (Fig. 1E). Similar results were also observed when LIF is blocked using a LIF-neutralizing antibody (LIFAb) in reprogramming (Supplementary Figs. S1, S2). Thus, the LIF regulated Jak activity specifically stimulates pluripotency marker genes including *Esrrb* that are tightly associated with pluripotency development during the somatic cell reprogramming process.

***Esrrb* Promotes Complete Reprogramming in the Presence of Jak/Stat3 Inhibition**

We wanted to evaluate the functional significance of these pluripotent genes regulated by Jak/Stat3 activity for complete reprogramming. We utilized the pre-iPSCs isolated at 3-week reprogramming point (Fig. 1A), which remained GFP-negative and a continuous OKSM transgene expression under Jaki treatment (Tang et al., 2012). Overexpressing a constitutively active form of Stat3 (Stat3C) (Bromberg et al., 1999) in these pre-iPSCs led to significantly increased GFP positive (GFP+) colonies within 2 weeks in the presence of Jaki, further confirming a specific blocking of Stat3 signaling by Jaki treatment in halted reprogramming (Fig. 2A). We tested three candidate genes (*Esrrb*, *Nanog*, and *Nr5a2*) for their overexpression on reprogramming of the pre-iPSCs. We chose these genes since *Nanog* was shown to upregulate *Esrrb* in ESCs (Festuccia et al., 2012), and *Nr5a2* was reported as a Wnt regulated transcription factor that can stimulate the expression of *Oct4*, *Nanog*, and *Tbx3* in ESCs (Wagner et al., 2010), and can replace *Oct4* for iPSC induction (Heng et al., 2010). Out of multiple trials, we consistently observed a significant increase of GFP+ colonies in 2-3 weeks by overexpression of *Esrrb* (to around 25% of the GFP+ colonies developed in the absence of Jaki), whereas overexpressing *Nanog* or *Nr5a2* had negligible effect (Fig. 2A). Similar results were obtained when we

overexpressed *Esrrb*, *Nanog*, *Nr5a2*, and three other genes (*Klf2*, *Lin28*, and *Prdm14*) using two additional lines of pre-iPSCs (Supplementary Fig. S3).

The GFP⁺ colonies induced by *Esrrb* overexpression can be further expanded in 2i/LIF, the restrictive medium for ground state pluripotency (Silva et al., 2009; Ying et al., 2008) (Fig. 2B). In contrast to their parental pre-iPSCs, the *Esrrb*-induced iPSCs showed expression of endogenous pluripotent genes at levels comparable to ESCs, including *Oct4*, *Sox2*, *Klf4*, *Nanog*, *Rex1*, *Dppa3*, and *Nr5a2*, and silenced the transgene expression (Fig. 2C, Supplementary Fig. S4). Furthermore, upon removal of the LIF cytokine, these *Esrrb*-induced iPSCs readily formed embryoid bodies (EBs), with gradual silencing of the Oct4-GFP fluorescence (Fig. 2D), and demonstrated three-germ layer differentiation (Fig. 2E, Supplementary Figs. S5). These iPSCs also showed the ability of differentiation into beating cardiomyocytes (Supplementary online Video 1). Taken together, our data demonstrate that during somatic cell reprogramming, the activation of *Esrrb* is one of the key effectors downstream of Jak/Stat3 for the complete pluripotency establishment.

The Expression of *Esrrb* Depends on LIF/Jak Pathway Activity in Reprogramming

Esrrb has been reported to be regulated by *Nanog* in ESCs (Festuccia et al., 2012). In this study we found that *Esrrb* but not *Nanog* overexpression could resume the reprogramming of pre-iPSCs with inhibited Jak/Stat3 activity (Fig. 2A, Supplementary Fig. S3). This result is also consistent with our previous study showing that with the absence of LIF, the addition of *Nanog* overexpression cannot rescue the GFP⁺ iPSC

generation from OG-MEFs transduced with retroviral OKSM(Tang et al., 2012). We then wondered whether Nanog would stimulate Esrrb expression during the reprogramming in depleted LIF signaling. qRT-PCR analysis to these previously reprogrammed samples at 3-week time point further revealed that without LIF cytokine, there is no significant increase in Esrrb expression in the reprogrammed cells compared with the OKSM transduction, despite a high level of Nanog transgene overexpression (Fig. 3A).

Esrrb is also the Wnt pathway downstream effector that supports ESC self-renewal, which can be activated through suppression of GSK3 by a specific inhibitor CHIR99021 (CHIR)(Martello et al., 2012). We wondered whether Esrrb could be similarly activated during the reprogramming process without LIF pathway signaling. We added CHIR to the pre-iPSC medium treated by Jaki or LIFAb. The pre-iPSCs cultured in LIF cytokine-containing medium developed GFP+ colonies in 12 days, while the cells treated with Jaki or LIFAb remained GFP-negative (Fig. 3B). The addition of CHIR to either Jaki or LIFAb condition showed no improvement on GFP+ colony generation from pre-iPSCs (Figs. 3B, 3C). However, CHIR increased the number of GFP-negative colonies, resulting in a significantly greater number of total colonies developed during the pre-iPSC reprogramming process (Figs. 3D, S6). qRT-PCR analysis revealed that the addition of CHIR did not activate the expression of Esrrb in the pre-iPSCs treated with Jaki or LIFAb (Fig. 3E). Thus, in the absence of LIF/Jak/Stat3 signaling, the Wnt activity alone cannot induce Esrrb expression during the reprogramming, even though inhibition of GSK3 does stimulate the development of partially reprogrammed colonies. Taking together, our data strongly indicate that the expression of Esrrb is determined by LIF/Jak

activity during the reprogramming process, and *Esrrb* serves as a LIF/Jak downstream effector important for the generation of completely reprogrammed iPSCs.

Discussion

The LIF regulated Jak/Stat3 pathway is important for naïve-state pluripotency establishment across species(Weinberger et al., 2016). Although many downstream targets of Stat3 have been reported, the complete understanding of Jak/Stat3 mediated pluripotency establishment has not been achieved. Jak/Stat3 signaling has been reported to regulate pluripotency in pluripotent stem cells through a number of transcription factors such as *Tfcp2l1* and *Klf4*(Hall et al., 2009; Martello et al., 2013; Niwa et al., 2009; Ye et al., 2013). However, how Jak/Stat3 regulates its downstream targets in reprogrammed somatic cells to achieve complete pluripotency is not well understood. We found that in mouse iPSC generation, LIF stimulated Jak activity regulates the activation of a number of key pluripotent factors such as *Esrrb*. To our best knowledge this is the first report demonstrating *Esrrb* as a downstream target of LIF/Jak signaling in somatic cell reprogramming. *Esrrb* is a naïve-specific pluripotency marker negatively regulated by GSK3/Tcf3 in ESCs, and overexpressing it can sustain ESC pluripotency similarly as the Wnt signal activation(Martello et al., 2012). *Esrrb* is also a *Nanog* target, and overexpressing *Esrrb* promotes complete reprogramming from *Nanog*-null pre-iPSCs, and sustains LIF-independent ESC self-renewal similarly as *Nanog*(Festuccia et al., 2012). We found that inhibiting Jak/Stat3 or LIF results in the lack of *Esrrb* activity, and overexpressing *Esrrb* in pre-iPSCs resumes reprogramming despite the inhibited

Jak/Stat3. However, in the case of blocked LIF or Jak/Stat3 activity, overexpression of Nanog or mimicking the canonic Wnt signaling by inhibiting GSK3 – the two known regulators of Esrrb in ESCs could not stimulate the expression of Esrrb nor could they promote the complete reprogramming. Our finding highlights the multiple layers of upstream control for Esrrb expression, which changes between the reprogramming and pluripotency maintenance stages. Our results indicate that during the reprogramming process, the activation of Esrrb relies on LIF stimulated Jak/Stat3 activity. Activated Esrrb can then serve as an important LIF downstream effector driving the cells towards complete reprogramming, and becomes the essential component parallel to LIF signaling for pluripotency maintenance as previously described (Martello et al., 2012).

We also noticed that in the absence of LIF signaling, CHIR mediated GSK3 inhibition results in an increased GFP-negative colony formation in pre-iPSC reprogramming. Multiple mechanisms could be responsible for this phenomenon, as Wnt regulates many downstream targets via suppressing GSK3 activity (Beurel et al., 2015; Sokol, 2011). Firstly, relieving the GSK3 inhibition of glycogen synthase (Embi et al., 1980) may modulate glucose homeostasis and energy metabolism of reprogrammed cells in favor of a fast cell proliferation. Also, GSK3 can interact with and be activated by p53 during cellular DNA damage, resulting in increased apoptotic response (Watcharasit et al., 2002). We recently showed that knockdown of Akt3 in ESCs activates p53 signaling, leading to apoptosis and impaired cell proliferation (Wang et al., 2017a). We also found that inhibiting GSK3 promotes the reprogramming of MEFs inhibited by blocking Akt/PKB activity, which leads to cell apoptosis (Tang et al., 2014). Thus, inhibition of

GSK3 can enhance the survival of reprogrammed cells, as many of them committed p53- and other apoptotic factors- mediated cell death (Banito et al., 2009). Thirdly, the inhibition of GSK3 by Wnt signaling also results in increased nuclear β -catenin activity that is required for ESC self-renewal (Kelly et al., 2011; Wray et al., 2011). On the other hand, in addition to Esrrb, inhibition of GSK3 may also release other factors suppressed by Tcf activity, thus enhancing the cell proliferation during reprogramming. The exact mechanism for this Esrrb-independent promotion of colony development would be very interesting to investigate.

Recently, a number of studies revealed that naïve-state pluripotency can also be established in human ESCs/iPSCs (Wang and Gao, 2016; Ware, 2017). However, it was also reported that unlike the naïve-pluripotent mouse ESCs, the naïve-state human cells exhibit little Esrrb expression, which might account for their instability in propagation compared with their mouse counterparts (Guo et al., 2016). Understanding the Esrrb mediated naïve pluripotency maintenance, as well as its activation during reprogramming may uncover novel routes for improvement of naïve-state human pluripotent stem cells. In light of this view, it was recently reported that Esrrb activates the oxidative phosphorylation process in reprogrammed cells, which is essential for efficient reprogramming and conversion of the primed-state pluripotency into naïve-state (Sone et al., 2017). How exactly the LIF/Jak/Stat3 signaling determines the Esrrb expression during mouse iPSC generation is currently under investigation. Nevertheless our study here demonstrates that LIF/Jak signaling dictates the activation of Esrrb in somatic cells

during reprogramming as one of its significant downstream effectors for the pluripotency establishment.

Conclusion

We identified LIF/Jak activity-specific regulation and activation of several pluripotency-predicting genes including *Esrrb*. Functional analysis revealed that *Esrrb* overexpression rescues the reprogramming halted by the inhibited LIF/Jak/Stat3 activity, and leads to the generation of pluripotent iPSCs. We further show that during the reprogramming process, *Esrrb* serves as a LIF activity - dependent downstream effector, with its expression unstimulated by Nanog or Wnt activity when LIF/Jak signaling is missing. Our data provide new insight for LIF signaling pathway mediated pluripotency establishment in reprogramming, which are valuable for further improving the generation of naïve-state iPSCs across species.

Acknowledgement

This work was supported by the USDA W2171 regional project to Y.T., the Agriculture and Food Research Initiative Competitive Grant no. 2016-67016-24894 to Y.T. from the USDA National Institute of Food and Agriculture, and the Chinese Scholarship Council for Study Abroad for D.H. and M.Z..

Conflict of Interest

The authors declare that no conflict of interest exists here.

References

- Aksoy, I., Sakabedoyan, C., Bourillot, P. Y., Malashicheva, A. B., Mancip, J., Knoblauch, K., Afanassieff, M. and Savatier, P.** (2007). Self-renewal of murine embryonic stem cells is supported by the serine/threonine kinases Pim-1 and Pim-3. *STEM CELLS* **25**, 2996-3004.
- Banito, A., Rashid, S. T., Acosta, J. C., Li, S., Pereira, C. F., Geti, I., Pinho, S., Silva, J. C., Azuara, V., Walsh, M. et al.** (2009). Senescence impairs successful reprogramming to pluripotent stem cells. *Genes Dev* **23**, 2134-9.
- Beurel, E., Grieco, S. F. and Jope, R. S.** (2015). Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. *Pharmacol Ther* **148**, 114-31.
- Bromberg, J. F., Wrzeszczynska, M. H., Deyuan, G., Zhao, Y., Pestell, R. G., Albanese, C. and Darnell, J. E., Jr.** (1999). Stat3 as an oncogene. *Cell* **98**, 295-303.
- Buganim, Y., Faddah, D. A., Cheng, A. W., Itskovich, E., Markoulaki, S., Ganz, K., Klemm, S. L., van Oudenaarden, A. and Jaenisch, R.** (2012). Single-cell expression analyses during cellular reprogramming reveal an early stochastic and a late hierarchic phase. *Cell* **150**, 1209-22.
- Cartwright, P., McLean, C., Sheppard, A., Rivett, D., Jones, K. and Dalton, S.** (2005). LIF/STAT3 controls ES cell self-renewal and pluripotency by a Myc-dependent mechanism. *Development* **132**, 885-96.
- Casanova, E. A., Shakhova, O., Patel, S. S., Asner, I. N., Pelczar, P., Weber, F. A., Graf, U., Sommer, L., Burki, K. and Cinelli, P.** (2011). Prdm17 mediates LIF/STAT3-dependent self-renewal in embryonic stem cells. *STEM CELLS* **29**, 474-85.
- De Los Angeles, A., Loh, Y. H., Tesar, P. J. and Daley, G. Q.** (2012). Accessing naive human pluripotency. *Curr Opin Genet Dev* **22**, 272-82.
- Embi, N., Rylatt, D. B. and Cohen, P.** (1980). Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. *Eur J Biochem* **107**, 519-27.
- Festuccia, N., Osorno, R., Halbritter, F., Karwacki-Neisius, V., Navarro, P., Colby, D., Wong, F., Yates, A., Tomlinson, S. R. and Chambers, I.** (2012). Esrrb is a direct Nanog target gene that can substitute for Nanog function in pluripotent cells. *Cell Stem Cell* **11**, 477-90.
- Guo, G., von Meyenn, F., Santos, F., Chen, Y., Reik, W., Bertone, P., Smith, A. and Nichols, J.** (2016). Naive Pluripotent Stem Cells Derived Directly from Isolated Cells of the Human Inner Cell Mass. *Stem Cell Reports* **6**, 437-46.
- Hall, J., Guo, G., Wray, J., Eyres, I., Nichols, J., Grotewold, L., Morfopoulou, S., Humphreys, P., Mansfield, W., Walker, R. et al.** (2009). Oct4 and LIF/Stat3 additively induce Kruppel factors to sustain embryonic stem cell self-renewal. *Cell Stem Cell* **5**, 597-609.
- Heng, J. C., Feng, B., Han, J., Jiang, J., Kraus, P., Ng, J. H., Orlov, Y. L., Huss, M., Yang, L., Lufkin, T. et al.** (2010). The nuclear receptor Nr5a2 can replace Oct4 in the reprogramming of murine somatic cells to pluripotent cells. *CELL STEM*

CELL **6**, 167-74.

Kelly, K. F., Ng, D. Y., Jayakumar, G., Wood, G. A., Koide, H. and Doble, B. W. (2011). beta-catenin enhances Oct-4 activity and reinforces pluripotency through a TCF-independent mechanism. *Cell Stem Cell* **8**, 214-27.

Martello, G., Bertone, P. and Smith, A. (2013). Identification of the missing pluripotency mediator downstream of leukaemia inhibitory factor. *Embo J* **32**, 2561-74.

Martello, G., Sugimoto, T., Diamanti, E., Joshi, A., Hannah, R., Ohtsuka, S., Gottgens, B., Niwa, H. and Smith, A. (2012). Esrrb is a pivotal target of the Gsk3/Tcf3 axis regulating embryonic stem cell self-renewal. *Cell Stem Cell* **11**, 491-504.

Matsuda, T., Nakamura, T., Nakao, K., Arai, T., Katsuki, M., Heike, T. and Yokota, T. (1999). STAT3 activation is sufficient to maintain an undifferentiated state of mouse embryonic stem cells. *EMBO J* **18**, 4261-9.

Nichols, J. and Smith, A. (2009). Naive and primed pluripotent states. *Cell Stem Cell* **4**, 487-92.

Niwa, H., Burdon, T., Chambers, I. and Smith, A. (1998). Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3. *Genes Dev* **12**, 2048-60.

Niwa, H., Ogawa, K., Shimosato, D. and Adachi, K. (2009). A parallel circuit of LIF signalling pathways maintains pluripotency of mouse ES cells. *Nature* **460**, 118-22.

Parisi, S., Passaro, F., Aloia, L., Manabe, I., Nagai, R., Pastore, L. and Russo, T. (2008). Klf5 is involved in self-renewal of mouse embryonic stem cells. *J Cell Sci* **121**, 2629-34.

Polo, J. M., Anderssen, E., Walsh, R. M., Schwarz, B. A., Nefzger, C. M., Lim, S. M., Borkent, M., Apostolou, E., Alaei, S., Cloutier, J. et al. (2012). A molecular roadmap of reprogramming somatic cells into iPS cells. *Cell* **151**, 1617-32.

Sheshadri, P., Ashwini, A., Jahnavi, S., Bhonde, R., Prasanna, J. and Kumar, A. (2015). Novel role of mitochondrial manganese superoxide dismutase in STAT3 dependent pluripotency of mouse embryonic stem cells. *Sci Rep* **5**, 9516.

Silva, J., Nichols, J., Theunissen, T. W., Guo, G., van Oosten, A. L., Barrandon, O., Wray, J., Yamanaka, S., Chambers, I. and Smith, A. (2009). Nanog is the gateway to the pluripotent ground state. *Cell* **138**, 722-37.

Smith, A. G., Heath, J. K., Donaldson, D. D., Wong, G. G., Moreau, J., Stahl, M. and Rogers, D. (1988). Inhibition of pluripotential embryonic stem cell differentiation by purified polypeptides. *Nature* **336**, 688-90.

Sokol, S. Y. (2011). Maintaining embryonic stem cell pluripotency with Wnt signaling. *Development* **138**, 4341-50.

Sone, M., Morone, N., Nakamura, T., Tanaka, A., Okita, K., Woltjen, K., Nakagawa, M., Heuser, J. E., Yamada, Y., Yamanaka, S. et al. (2017). Hybrid Cellular Metabolism Coordinated by Zic3 and Esrrb Synergistically Enhances Induction of Naive Pluripotency. *Cell Metab* **25**, 1103-1117 e6.

Stewart, C. L., Kaspar, P., Brunet, L. J., Bhatt, H., Gadi, I., Kontgen, F. and Abbondanzo, S. J. (1992). Blastocyst implantation depends on maternal expression of leukaemia inhibitory factor. *Nature* **359**, 76-9.

Tai, C. I. and Ying, Q. L. (2013). Gbx2, a LIF/Stat3 target, promotes reprogramming to and retention of the pluripotent ground state. *J Cell Sci* **126**, 1093-8.

- Takahashi, K. and Yamanaka, S.** (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126**, 663-76.
- Tan, G., Cheng, L., Chen, T., Yu, L. and Tan, Y.** (2014). Foxm1 mediates LIF/Stat3-dependent self-renewal in mouse embryonic stem cells and is essential for the generation of induced pluripotent stem cells. *PLoS One* **9**, e92304.
- Tang, Y., Jiang, Z., Luo, Y., Zhao, X., Wang, L., Norris, C. and Tian, X. C.** (2014). Differential effects of Akt isoforms on somatic cell reprogramming. *J Cell Sci* **127**, 3998-4008.
- Tang, Y., Luo, Y., Jiang, Z., Ma, Y., Lin, C. J., Kim, C., Carter, M. G., Amano, T., Park, J., Kish, S. et al.** (2012). Jak/Stat3 signaling promotes somatic cell reprogramming by epigenetic regulation. *Stem Cells* **30**, 2645-56.
- Thompson, J. E., Cubbon, R. M., Cummings, R. T., Wicker, L. S., Frankshun, R., Cunningham, B. R., Cameron, P. M., Meinke, P. T., Liverton, N., Weng, Y. et al.** (2002). Photochemical preparation of a pyridone containing tetracycline: a Jak protein kinase inhibitor. *Bioorg Med Chem Lett* **12**, 1219-23.
- van Oosten, A. L., Costa, Y., Smith, A. and Silva, J. C.** (2012). JAK/STAT3 signalling is sufficient and dominant over antagonistic cues for the establishment of naive pluripotency. *Nat Commun* **3**, 817.
- Wagner, R. T., Xu, X., Yi, F., Merrill, B. J. and Cooney, A. J.** (2010). Canonical Wnt/beta-catenin regulation of liver receptor homolog-1 mediates pluripotency gene expression. *STEM CELLS* **28**, 1794-804.
- Wang, L., Huang, D., Jiang, Z., Luo, Y., Norris, C., Zhang, M., Tian, X. and Tang, Y.** (2017a). Akt3 is responsible for the survival and proliferation of embryonic stem cells. *Biol Open* **6**, 850-861.
- Wang, L., Jiang, Z., Huang, D., Duan, J., Huang, C., Sullivan, S., Vali, K., Yin, Y., Zhang, M., Wegrzyn, J. et al.** (2017b). Jak/Stat3 Regulated Global Gene Expression Dynamics During Late-Stage Reprogramming Process. *Submitted*.
- Wang, Y. and Gao, S.** (2016). Human Naive Embryonic Stem Cells: How Full Is the Glass? *CELL STEM CELL* **18**, 301-3.
- Ware, C. B.** (2017). Concise Review: Lessons from Naive Human Pluripotent Cells. *STEM CELLS* **35**, 35-41.
- Watcharasil, P., Bijur, G. N., Zmijewski, J. W., Song, L., Zmijewska, A., Chen, X., Johnson, G. V. and Jope, R. S.** (2002). Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage. *Proc Natl Acad Sci U S A* **99**, 7951-5.
- Weinberger, L., Ayyash, M., Novershtern, N. and Hanna, J. H.** (2016). Dynamic stem cell states: naive to primed pluripotency in rodents and humans. *Nat Rev Mol Cell Biol* **17**, 155-69.
- Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gearing, D. P., Wagner, E. F., Metcalf, D., Nicola, N. A. and Gough, N. M.** (1988). Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells. *Nature* **336**, 684-7.
- Wray, J., Kalkan, T., Gomez-Lopez, S., Eckardt, D., Cook, A., Kemler, R. and Smith, A.** (2011). Inhibition of glycogen synthase kinase-3 alleviates Tcf3 repression of the pluripotency network and increases embryonic stem cell resistance to differentiation. *Nat Cell Biol* **13**, 838-45.

Yang, J., van Oosten, A. L., Theunissen, T. W., Guo, G., Silva, J. C. and Smith, A. (2010). Stat3 activation is limiting for reprogramming to ground state pluripotency. *CELL STEM CELL* **7**, 319-28.

Ye, S., Li, P., Tong, C. and Ying, Q. L. (2013). Embryonic stem cell self-renewal pathways converge on the transcription factor Tfcp2l1. *Embo J* **32**, 2548-60.

Ying, Q. L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J., Cohen, P. and Smith, A. (2008). The ground state of embryonic stem cell self-renewal. *Nature* **453**, 519-23.

Figures




Fig. 1: Esrrb Is Regulated by LIF and Jak/Stat3 Activity in Reprogramming

A: Schematic diagram depicting the reprogramming process and dates (S1 and S2) for RNA-seq sample collection from reprogrammed cells.

B: Heatmap of FPKM value comparison for key pluripotent genes plus the Stat3 activity indicator – Socs3 under Jaki or DMSO treatment at reprogramming stage S1 and S2. The relative abundance is represented by color (blue, lower abundance; red, higher

abundance), as indicated by the color key.

C: qRT-PCR analysis of pluripotent genes in reprogrammed cells collected at Jaki or DMSO treatment at reprogramming stage S1 and S2. Values are relative to R1-ESC standard. Bars represent mean \pm SD from three independent biological repeats.

Arrowhead: expression not detected. *: $p < 0.05$, **: $p < 0.01$.

D: Schematic diagram depicting the reprogramming process and dates for LIF-deprivation MEF reprogramming experiment.

E: qRT-PCR analysis of pluripotent genes in reprogrammed cells with or without LIF, or with LIF plus Jaki treatment at 3-week time point. Values are relative to R1-ESC standard. Bars represent mean \pm SD from two independent biological repeats.




Fig. 2: Esrrb Promotes Complete Reprogramming Blocked by Jak/Stat3 Inhibition.

A: pre-iPSCs were expanded and seeded into 24-well-plates, and infected with vector Ctl or virally expressed Stat3C, Esrrb, Nanog, or Nr5a2 and cultured in the presence of LIF or LIF plus Jaki. GFP+ colonies were counted at 2 weeks after viral infection. Bars represent mean±SD of four independent experiments. **: $p < 0.01$.

B: The Esrrb induced putative iPSC colonies cultured in 2i/LIF medium at different passages (p). Bar = 120 μm at p2 and 625 μm at p4.

C: qRT-PCR analysis of endogenous (eOct4, eSox2, eKlf4) and total (endogenous plus viral transgene) expression of reprogramming factors in Esrrb induced putative iPSC colonies at passage 3, together with the parental pre-iPSCs remaining in Jaki treatment. R1-ESC was used as the Ctl. Bars represent mean±SD from two different cell lines derived.

D: Embryoid body (EB) formation from original Esrrb-induced iPSCs at days 3 and 7 of differentiation, with gradually silenced Oct4-GFP expression (Bar = 250 μ m).

E: qRT-PCR analysis for relative expression levels of the three germ layer markers at day 14 of EB differentiation (Endoderm: AFP, ALB1; Mesoderm: Brachyury, Acta2; Ectoderm: Nestin). The gene expression values of two differentiated EB lines were relative to their parental iPSCs.




Fig. 3: Esrrb Expression Depends on LIF and Jak Activity in Reprogramming.

A: qRT-PCR analysis for pluripotent genes in reprogrammed cells transduced with retroviral 4F (OKSM) or 4F plus Nanog, with or without LIF cytokine at 3-week time point. Values are relative to R1-ESC standard. The endogenous and total (endo- plus viral-expression) Nanog (eNanog and tNanog, respectively) expressions were also shown. Bars represent mean±SD from two independent biological repeats. **: $p < 0.01$.

B: Representative images of pre-iPSCs seeded into 24-well-plates and treated with LIF, LIF plus Jaki, LIF plus Jaki/CHIR, LIFab, or LIFab/CHIR at day 12 of reprogramming (Bar = 250 μ m).

C: GFP+ colonies induced from pre-iPSCs treated as described in 3B were counted at day 12. Bars represent mean±SD of three independent experiments. **: $p < 0.01$.

D: Number of total colonies developed from pre-iPSC reprogramming as described in 3B at day 12. Bars represent means of three independent experiments. **: $p < 0.01$.

E: qRT-PCR analysis for Esrrb, Sox2, and Nanog expression in pre-iPSCs treated with Jaki, Jaki plus CHIR, LIFAb, or LIFAb plus CHIR at reprogramming day 12. Values are relative to R1-ESC standard. Bars represent mean \pm SD from three independent experiments. **: $p < 0.01$.

Supplementary Figures

Fig. S1: Schematic diagram depicting the MEF reprogramming process and dates for LIF and LIFAb treatments and sample collection.




Fig. S2: Key Pluripotent Genes Downregulated by Blocking LIF Signaling in Reprogramming.

qRT-PCR analysis of key pluripotent gene expressions in MEF reprogramming treated with LIF or LIFAb at 2- and 3-week time points. Bars represent mean from triplicate wells. R1-ESC was used as the control.




Fig. S3: Esrrb Promotes Complete Reprogramming Despite Jak/Stat3 Inhibition.

Jaki-treated pre-iPSC lines (P6J1 and P6J2) were expanded and seeded into 24-well-plates and infected with vector Ctl or virally expressed Esrrb, Nanog, Klf2, Nr5a2, Lin28, or Prdm14 and cultured in the presence of LIF or LIF plus Jaki. GFP+ colonies were counted at 2 weeks after viral infection. Bars represent mean±SD from two independent experiments. **: $p < 0.01$.




Fig. S4: Putative Esrrb-induced iPSCs Express Pluripotent Markers.

qRT-PCR analysis of endogenous pluripotent markers for Esrrb induced putative iPSC colonies and the parental pre-iPSCs. R1-ESC was used as the Ctl. Bars represent mean±SD from two different cell lines derived.




Fig. S5: Three-Germ Layer Differentiation of Esrrb-induced Putative iPSCs (Immunostaining).

Immunostaining for the expression of the three germ layer markers at day 14 of EB differentiation (Endoderm: Gata4; Mesoderm: Brachyury; Ectoderm: Otx2). Primary antibodies were conjugated with NL493 or NL557 fluorochromes. Cell nuclei were counterstained with DAPI. The differentiated cells not stained with antibodies (Ctl) showed no NL493 and NL557 fluorescence signals. (Bar = 120 μ m).




Fig. S6: Representative images of pre-iPSCs seeded into 24-well-plates and treated with LIF plus Jaki, LIF plus Jaki/CHIR, LIFAb, or LIFAb/CHIR at day 12 (Bar = 625 μ m).



Supplementary Online Video 1



Supplementary online Video 1: Beating cardiac cell formation from Esrrb-induced iPSCs upon EB formation at day 14.